← All trials
NCT03783429
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2019
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 982
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of GroningenLead sponsor
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- University of GroningenOverall official - principal investigator
- University of GroningenReponsible party - principal investigator
- Tiofarma BVCollaborator
- TevaCollaborator
- Netherlands Heart FoundationCollaborator
- Disphar International B.V.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.